Skip to content

Upadacitinib

Janus Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: ABT-494, rinvoq, upadacitinib hydrate

OnpEMA approvedFDA approvedPMDA approvedATC L04AF03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Upadacitinib is an onp drug in the Janus Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Janus Kinase Inhibitors. DrugCentral lists 26 molecular targets, including JAK1, JAK2 and ROCK2. Recorded indications include Ankylosing spondylitis, Atopic dermatitis, Crohn's disease and Nonradiographic axial spondyloarthritis.

  • Approval status: onp (first approved 2019 by the FDA).
  • Drug class: Janus Kinase Inhibitor.
  • Mechanism of action: Janus Kinase Inhibitors.
  • Molecular targets: JAK1, JAK2, ROCK2 and Jak2 (26 listed in DrugCentral).
  • Indications: Ankylosing spondylitis, Atopic dermatitis, Crohn's disease, Nonradiographic axial spondyloarthritis and Psoriatic arthritis and others.
  • ATC code: L04AF03 (Janus-associated kinase (JAK) inhibitors).
  • Molecular formula: C17H19F3N6O; molecular weight 380.38 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

  • Ankylosing spondylitis
  • Atopic dermatitis
  • Crohn's disease
  • Nonradiographic axial spondyloarthritis
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis

Mechanism & targets

Mechanism of action (MoA)Janus Kinase Inhibitors
Established pharmacologic classJanus Kinase Inhibitor

Molecular targets (26)

TargetGeneActionActivity
Tyrosine-protein kinase JAK1JAK1inhibitorIC50 7.33
Tyrosine-protein kinase JAK2JAK2inhibitorIC50 6.92
Rho-associated protein kinase 2ROCK2unknownIC50 6.38
Tyrosine-protein kinase JAK2Jak2unknownIC50 6.23
Rho-associated protein kinase 1ROCK1unknownIC50 6.04
Vascular endothelial growth factor receptor 2KDRunknownIC50 5.82
Tyrosine-protein kinase JAK3Jak3unknownIC50 5.73
Cyclin-G-associated kinaseGAKunknownKd 5.66
Calcium/calmodulin-dependent protein kinase type 1DCAMK1DunknownIC50 5.64
Tyrosine-protein kinase JAK3JAK3inhibitorIC50 5.63
Proto-oncogene tyrosine-protein kinase receptor RetRETunknownIC50 5.62
Non-receptor tyrosine-protein kinase TYK2Tyk2unknownIC50 5.57
Leukocyte tyrosine kinase receptorLTKunknownIC50 5.57
5'-AMP-activated protein kinase catalytic subunit alpha-1PRKAA1unknownIC50 5.35
Aurora kinase AAURKAunknownIC50 5.35
Non-receptor tyrosine-protein kinase TYK2TYK2inhibitorIC50 5.33
Fibroblast growth factor receptor 1FGFR1unknownIC50 5.32
Activated CDC42 kinase 1TNK2unknownIC50 5.29
Protein kinase C theta typePRKCQunknownIC50 5.29
Aurora kinase BAURKBunknownIC50 5.26

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2020-01-23PMDA—AbbVie GK
2019-12-16EMA—AbbVie Deutschland GmbH & Co. KG
2019-08-16FDA—ABBVIE INC

ATC classification

ATC codeTherapeutic hierarchy
L04AF03ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Janus-associated kinase (JAK) inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: CYP2D6
  • FDA label: CYP2D6 · No Clinical PGx
  • HCSC label: CYP2D6 · No Clinical PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Therapy interrupted4928.7
COVID-191091.7
Product residue present832.8
Illness822.6
Acne799.2
Herpes zoster798.1
Intentional dose omission415.5
Drug ineffective284.7
Surgery284.3
Urinary tract infection270.8
Eczema herpeticum244.5
Therapy cessation243.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Upadacitinib is on its molecule page.

Molecular formulaC17H19F3N6O
Molecular weight380.38 g/mol
CAS number1310726-60-3
InChIKeyWYQFJHHDOKWSHR-MNOVXSKESA-N
PubChem CID58557659
CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Upadacitinib used for?

DrugCentral lists the following indications for Upadacitinib: Ankylosing spondylitis, Atopic dermatitis, Crohn's disease, Nonradiographic axial spondyloarthritis, Psoriatic arthritis, Rheumatoid arthritis and Ulcerative colitis.

How does Upadacitinib work?

Upadacitinib is classified as Janus Kinase Inhibitors; its molecular targets in DrugCentral include JAK1 (inhibitor), JAK2 (inhibitor), ROCK2 and Jak2.

When was Upadacitinib first approved?

Upadacitinib was first approved by the FDA in 2019.

What drug class does Upadacitinib belong to?

Upadacitinib is in the Janus Kinase Inhibitor class.

What is the chemical formula of Upadacitinib?

Upadacitinib has the molecular formula C17H19F3N6O and a molecular weight of 380.38 g/mol.

Browse: all drugs starting with U · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2019-08-16
AgencyFDA
Targets26
Indications7
FormulaC17H19F3N6O
DrugCentral ID5346
Interactive profile